StockData

Elanco Animal Health vs IDEXX Laboratories

ELAN and IDXX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELAN and IDXX compare

IDEXX Laboratories is the larger company, worth 4.2 times as much as Elanco Animal Health ($54.4B against $12.9B).

IDEXX Laboratories grew revenue faster over the last twelve months (12.8% versus 12.0% for Elanco Animal Health).

IDEXX Laboratories keeps more of each dollar of sales as profit, with a net margin of 25.0% compared with −4.0% at Elanco Animal Health.

IDEXX Laboratories scores higher on the StockData Score (19 against 9 for Elanco Animal Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELANIDXX
Size and price
Market cap$12.9B$54.4B
Share price$25.85$690.24
Change, 1 year22.6%0.04%
Change, 5 years−14.5%13.6%
Beta (5Y)0.120.34
Employees9,40011K
StockData Score
Total score919 (better)
Valuation score12 (better)
Growth score35 (better)
Performance score36 (better)
Health score26 (better)
Dividend score00
Valuation
P/E–48.5×
P/S2.6× (better)11.9×
P/B2.0× (better)33.7×
EV/EBITDA30.9× (better)33.9×
P/FCF34.1× (better)43.4×
PEG–2.75
FCF yield2.9% (better)2.3%
Fair value$11.31$509.32
Margin of safety−129%−35.5% (better)
Growth
Revenue growth (TTM)12.0%12.8% (better)
Revenue growth, 5Y average7.6%9.7% (better)
Net income growth (TTM)−146%15.6% (better)
EPS growth (TTM)−149%18.4% (better)
EPS growth, 5Y average–14.3%
Profitability
Gross margin55.4%62.4% (better)
Operating margin–32.0%
Net margin−4.0%25.0% (better)
FCF margin7.5%27.5% (better)
Return on equity−3.0%74.2% (better)
Return on invested capital–63.3%
Financial health
Debt / equity0.590.28 (better)
Net debt / EBITDA6.430.16 (better)
Interest coverage–38.6×
Current ratio2.05 (better)1.17
Altman Z-score1.4423.48 (better)
Piotroski F-score68 (better)
Dividends and buybacks
Buyback yield–2.2%
Shareholder yield0.00%2.2% (better)
Ownership
Held by institutions113%94.5%
Held by insiders1.1%0.29%
Insider net buying, 12 months$2.5M (better)−$58.4M
Superinvestors holding–3
Short interest, % of float6.7%3.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.